Unfortunately things aren't as good as they seem. Over the past five years, it looks as though Pfizer's EPS has declined at around 23% a year. This steep decline can indicate that the business is ...

Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's ...

The 'Dogs of the Dow' strategy can be applied to Pfizer in 2025 for its 6.4% dividend and a former 'Dog.'. PFE's growth recovery, historical cheap valuation, and positive investment sentiment make ...

After Pfizer recalled a prescription drug used to treat sickle-cell disease, a newly filed class action complaint is claiming the company knew the medication causes painful and life-threatening ...

Pfizer reiterated its forecast for 2024 and issued a new one for 2025. Management generally tried to calm some worries from rattled shareholders. There are still a couple of issues to be aware of.

Investors with a lot of money to spend have taken a bullish stance on Pfizer PFE. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Pfizer has had a difficult time in recent years as demand for its coronavirus products declined. The company’s share price has reflected the tough times, falling more than 50% over three years.

Pfizer advances second-generation C. diff vaccine with Phase 2 data expected in 2025. Analyst maintains cautious optimism as investor sentiment remains muted on vaccine efforts. Pfizer hosted a ...

Pfizer’s research partnership with Sangamo Therapeutics produced a hemophilia A gene therapy that reached FDA discussions about a regulatory submission. That’s as far as the alliance will go.

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...